Biogen, Viagene Inc. deal

VIGN (San Diego) acquired a worldwide non-exclusive license for the use of the Cambridge, Mass., company's hepatitis B virus genes in gene therapy treatments for chronic HBV infection. VIGN expects to begin clinical studies this year.

BGEN received an undisclosed license fee and will receive royalties. BGEN will also retain certain marketing rights. ...